Use of Japanese encephalitis vaccine in children : recommendations of the Advisory Committee on Immunization Practices, 2013

Details

• Journal Article:
  MMWR. Morbidity and mortality weekly report
• Personal Author:
  Bocchini, Joseph A. ; Rubin, Lorry ; Fischer, Marc ; Hills, Susan L. ; Staples, J. Erin
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases.
• Description:
  On June 19, 2013, the Advisory Committee on Immunization Practices (ACIP) voted to extend existing recommendations for use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) (Ixiaro, Intercell Biomedical) to include children aged 2 months through 16 years. The ACIP JE Vaccine Workgroup reviewed the epidemiology of JE in travelers and evaluated published and unpublished data on JE-VC immunogenicity and safety in adults and children. The evidence for benefits and risks associated with JE-VC vaccination of children was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. This report summarizes the evidence considered by ACIP and outlines the recommendations for use of JE-VC in children traveling to JE-endemic countries.
  
  Citation: Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. MMWR Morb Mortal Wkly Rep. 2013 Nov 15;62(45):898-900.
  
  PMID: 24226626
  
  
• Content Notes:
  EMBeltrami
  
  9/02/2015
  
  
• Subjects:
  Adolescent Advisory Committees Child Child, Preschool Encephalitis, Japanese/epidemiology Encephalitis, Japanese/prevention & Control Immunization Schedule Infant Japanese Encephalitis Vaccines/adverse Effects Japanese Encephalitis Vaccines/immunology Japanese Encephalitis Vaccines/therapeutic Use Randomized Controlled Trials As Topic Risk Assessment Travel Vaccines, Inactivated/adverse Effects Vaccines, Inactivated/immunology Vaccines, Inactivated/therapeutic Use

  More +
• Source:
  MMWR. Morbidity and mortality weekly report ; v. 62, no. 45, p. 898-900
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• Document Type:
  Journal Article
• Genre:
  Practice Guideline
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  3 pages (p. 898-900)
• Volume:
  62
• Issue:
  45
• Collection(s):
  Guidelines and Recommendations Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:4e2e16019028e0227ea2d306d0840d674eea0358dfc3d07ea71e2b904e434ff7b81d7a5b6ea1e9b6bddd603b1346fe8bd422686761e3105fe5bc3322b73cb3d9
• Download URL:
  https://stacks.cdc.gov/view/cdc/34724/cdc_34724_DS1.pdf
• File Type:
  [PDF - 201.04 KB ]